# ChemComm

Accepted Manuscript








ROYAL SOCIETY OF CHEMISTRY

www.rsc.org/chemcomm

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

# Highly versatile convergent/divergent "onion peel" strategy toward potent multivalent glycodendrimers

**Rishi Sharma, Naresh Kottari, Yoann M. Chabre, Leïla Abbassi, Tze Chieh Shiao, and René Roy***

***Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX***

**DOI: 10.1039/b000000x**

**Both convergent and divergent strategies for the synthesis of "onion peel" glycodendrimers are reported which resulted in one of the best multivalent ligand known against the virulent factor from bacterial lectin isolated from *Pseudomonas aeruginosa*.**

Dendrimers are well defined, hyperbranched tree like macromolecules which have shown great potential for applications in diverse areas ranging from nanoengineering to medicine.[1] Their striking architecture leads to excellent properties, but unfortunately brings in many synthetic challenges as well. Traditionally, their iterative construction emanates from a central core in a layer by layer fashion using repetitive moieties *via* most popular divergent[2] and convergent[3] methods. Both strategies have their own drawbacks and often require tedious repetitive synthetic steps, with classically only a slow enhancement in the number of peripheral functionalities at each generation. To meet the increasing demand of dendrimers for advanced applications, the scientific focus has been shifted towards their efficient and rapid construction involving a minimum number of reactions and with access to a large number of surface active functionalities. Notably, the introduction of orthogonal building blocks, the use of hyperfunctionalized synthons combined to robust and highly efficient chemical reactions has recently fulfilled these specifications.[4-6]

Glycodendrimers in particular, with their widespread applications[7] as microbial antiadhesins, biosensors, vaccines, drug delivery, and gene transfection do not depart from this efficacy pursuit. In this context, we recently reported a novel divergent "onion peel" approach to construct glycodendrimers using distinct and orthogonal building blocks at each generation growth.[8] With this strategy, we demonstrated that structural diversities could be efficiently and rapidly harnessed at low generation. Notably, distinct hydrophobic/hydrophilic and rigidity/flexibility balances together with different epitopes' presentations clearly influenced their potencies as protein ligands. In complement to this rationally programmed arrangement of branching units, we wish to report herein the inverted strategy with the multivalent presentation of different types of ligands around a fixed "onion peel" dendritic scaffold. Chemically heterogeneous layers were assembled at each generation in both convergent and divergent strategies using a combination of orthogonal building blocks and highly efficient chemical reactions such as radical initiated photochemical thiol-ene reaction (TEC),[5,9] amidation,[10] and copper-catalyzed azide-alkyne cycloadditions (CuAAc).[11]

The divergent construction of these novel dendrimers was initiated with inexpensive commercially available dipentaerythritol **1** serving as a dense $A_6$ core. Per-*O*-allylation with allyl bromide in the presence of NaH in DMF provided *hexakis*allylated G(0) derivative **2** in 80% yield (Scheme 1). Complete allylation was clearly confirmed by $^1$H NMR, which showed the characteristic allylic signals at δ 5.90 and 5.34-5.08 ppm and the disappearance of OH signals together with its predicted HRMS. Core structure **2** was next subjected to radical TEC reaction with excess of cysteamine hydrochloride in the presence of photoinitiator 2,2 dimethoxy-2-phenylacetophenone (DMPAP, 10 mol%) under UV irradiation at 365 nm in DMF. Water soluble hydrochloride **3** was uneventfully isolated in 75% yield after dialysis and fully characterized by $^1$H- and $^{13}$C-NMR spectroscopy that showed the absence of olefinic signals, and by HRMS. Polyamine **3** was then treated with tripropargylated gallic acid derivative **4**[12] by amidation under classical carbodiimide coupling (72%). Notably, the use of $AB_3$ monomer **4**, when combined to our $A_6$ core **2**, readily provided G(1) hypercore **5** already possessing eighteen surface functional groups. For comparison purposes, PAMAM dendrimers and the like, built around $AB_2$ monomers, only reach these values at the G(2) level. Dendrimer **5** was next treated with peracetylated β-D-galactopyranosyl azide **6**[13] under classical click reaction conditions ($CuSO_4 \cdot 5H_2O$, Na-ascorbate in THF/$H_2O$) to afford octadecavalent galactodendrimer **7**. $^1$H-NMR spectrum showed the complete disappearance of the propargylic C≡C*H* signals at δ 2.50 ppm and the expected appearance of two distinct triazole signals integrating in a 2:1 ratio at δ 8.09 and 8.16 ppm. Another evidence for the monodispersity of the dendritic structure was further confirmed by gel permeation chromatography (GPC) which showed a narrow and symmetrical Gaussian pattern with a PDI of 1.03. Subsequently, de-*O*-acetylation of **7** under Zemplén conditions (NaOMe, MeOH) provided the final glycodendrimer **8** having 18 deprotected galactopyranoside moieties in quantitative yield (a molecule having 72-OH groups)!




**Scheme 1** Divergent and convergent synthesis of octadecavalent galactodendrimer **8**. *Reagents and conditions*: (*i*) NaH, Allyl bromide, DMF, 0ºC to rt, 5h, 80%; (*ii*) Cysteamine·HCl, DMPAP, DMF, 365 nm, 3h, 75%; (*iii*) EDC, DMAP, DIPEA, DMF, 60°C, o.n., 72%; (*iv*) $CuSO_4·5H_2O$, Na ascorbate, THF/$H_2O$ (1:1), 40°C, 12h, 81%; (*v*) MeONa/MeOH, rt, o.n., 88%; (*vi*) EDC, DMAP, DMF, rt, o.n., 78%; (*vii*) $CuSO_4·5H_2O$, Na ascorbate, THF/$H_2O$ (1:1), 40°C, 5h, 84%; (*viii*) $Et_3SiH$, TFA, 0°C, 3h, DCM, 85%; (*ix*) AIBN, Dioxane, 75ºC, 5h, 53%.

In order to illustrate the full versatility of this "onion peel" strategy for the rapid access to structurally diversified dendrimers, we also envisaged the construction of dendrimer **7** by a convergent approach. This alternative was initiated with *S*-trityl cysteamine **9** prepared by a slight modification (SI, Scheme 1) of literature procedure.[14] Classical amidation conditions with **4** (EDC, DMAP, DMF) provided intermediate **10** in 78% yield. Cu-catalyzed click reaction was then performed in the presence of galactosyl azide **6** to afford wedged glycodendron **11** in 84% yield. Once again, the apparition of two discrete triazole singlets in $^1$H NMR with suitable integration (δ 8.04 and 8.15 ppm; 2:1 ratio), coupled with the disappearance of propargylic signals confirmed the triple grafting of the sugar ligand. Chemoselective deprotection of the thiol group using 5% TFA in the presence of $Et_3SiH$ as a cation scavenger afforded dendron **12** in excellent yield (85%), without any trace of disulfide side-products. The aromatic protons corresponding to the trityl group at δ 7.46-7.17 ppm completely disappeared. Notably, the triplet corresponding to the $CH_2$ in the α-position of tritylated thiol **11** at δ 2.50 ppm shifted down-field at δ 2.75 ppm. Final ligation of thiol **12** with *hexakis*allylated core **2** was achieved using thiol-ene coupling reaction (AIBN, Dioxane, 75ºC, 5h.) to provide pure glycodendrimer **7** in a 53% yield (30% yield under UV/DPAP). Hence, we clearly demonstrated that the convergent sequence could be applied toward the construction of functionalized "onion peel" glycodendrimers without substantial loss of efficiency (5 steps and 24% overall yield from **1** *vs* 4 steps and 35% for the divergent method).

It is well established that key factors for improving the overall avidity of glycodendritic architectures against bacterial and leguminous lectins through multivalent binding processes originate from: 1) the relative accessibility of the sugar ligands at the dendritic surfaces[8] and 2) the inner scaffold structures/valency themselves.[7c,15,16] In order to further our understanding and the rationalization of these features using the above unique flexible "onion peel" template from which emanated galactopyranoside ligands with different aglycones, glycodendrimers with longer penultimate spacers were next constructed. Hence, for lectin's better accessibility toward the sugar ligands, longer branching residues and the choice of the peripheral sugars should constitute improved design. Toward this goal, we synthesised both galactopyranoside and lactoside dendrimers with tetraethylene glycol (TEG) spacers (Scheme **2**).




**Scheme 2** a) Syntheses of monomeric azido precursors **16-17**, b) reference compounds **18-19** and c) lactoside derivative immobilized on the chip for SPR studies. *Reagents and conditions*: i) $BF_3·Et_2O$, DCM, 0°C to rt, 4h, 55%; ii) $NaN_3$, DMF, 90°C, o.n., 82%.

Treatment of galactopyranose pentaacetate **13** with monotosylated tetraethylene glycol **14**[17] under Lewis acid-catalyzed conditions ($BF_3·Et_2O$ in DCM) afforded compound **15** in 55% yield. Substitution of the tosylate in **15** by a terminal

azide function was readily accomplished using $NaN_3$ in DMF to give **16** in 82% yield. Analogously, coupling tosylated TEG derivative **14** onto its peracetylated lactose homolog, followed by substitution with azide were performed as previously described,[17] but better results were ultimately obtained through the *per*-benzoylated derivative **17**, which allowed easier purification and increased yields (see *SI* for protocol). Both azido-terminated sugar ligands **16** and **17** were coupled onto scaffold **5** *via* CuAAc to afford glycodendrimers **22** and **24** in 76-77% yields, which correspond to nearly quantitative individual coupling (Scheme 3).




**Scheme 3**. Synthesis of glycodendrimers **23** and **25**. *Reagents and conditions*: i) $CuSO_4 \cdot 5H_2O$, Na ascorbate, $THF/H_2O$, 40°C, 12h, 76%-**22**, 77%-**24**; ii) NaOMe, DCM, MeOH, pH 9-10, rt, o.n., 90%-**23**, 86%-**25**.

Unequivocally, both $^1H$ and $^{13}C$ NMR spectra indicated complete disappearance of propargylic signals and sugar incorporation with calculated relative integration. HRMS together with the presence of molecular ions and fragmentations corresponding to regular losses of carbohydrate moieties gave convincing proofs of structural integrity. Zemplén transesterification (NaOMe, MeOH) furnished two additional water soluble glycodendritic candidates **23** (90%) and **25** (86%) for comparative inhibition experiments with a bacterial lectin from *Pseudomonas aeruginosa*. Note that dendrimer **25** possesses 126 peripheral OH groups and thus, can serve on its own as an interesting precursor for further functionalization and applications!

In this context, the relative binding affinities of three novel glycodendrimers **8**, **23**, and **25** were evaluated by competitive surface plasmon resonance (SPR) using the galactoside specific bacterial lectin from the gram-negative bacteria *P. aeruginosa*.[6,18] This protein constitutes a virulence factor and is involved in the pathogenesis of the bacteria in cystic fibrosis patients. To suitably evaluate the beneficial presentation of the multivalent sugar ligands, monomeric standards **18**[19], **19** and **20** corresponding to mimetics of the peripheral saccharidic belt of each conjugate were synthesized. To this end, CuAAc conditions were applied on glycosyl azides **6**, **16**, and peracetylated derivative of **17**, respectively, in the presence of propargylic alcohol, followed by classical de-*O*-acetylation under the Zemplén conditions (see *SI* for protocols).

For the competitive inhibition studies, the lactoside derivative **21**[20] was immobilized onto the commercial SPR sensor chip (CM5) following the manufacturer's procedure. $IC_{50}$ values (Table 1) were determined from the pre-incubated mixtures of PA-IL lectin (1.5 µM) with increasing concentrations of monomers or glycodendrimers used as analytes over the surface of CM5-bound **21**.

**Table 1.** $IC_{50}$ values of glycodendrimers and their monomeric analogs derived from competitive inhibition SPR studies.

| Entry | Cpd | $IC_{50}$ (µM) | R.p.[a] | R.p./sugar[b] | β[b] |
|---|---|---|---|---|---|
| | | *Galactoside* | | | |
| 1 | **18** | 43 ± 1.5 | 1 | 1 | 11 |
| 2 | **8** | 0.22 ± 0.02 | 195 | 11 | |
| | | *TEG-Galactoside* | | | |
| 3 | **19** | 21 ± 1.5[c] | 2 | 2 | **32** |
| 4 | **23** | **0.037 ± 0.005** | **1162** | **65** | |
| | | *TEG-Lactoside* | | | |
| 5 | **20** | 958 ± 34 | 0.05 | 0.05 | 11 |
| 6 | **25** | 4.2 ± 0.4 | 10 | 0.6 | |

[a] Relative potency. [b] Potency enhancement of individual sugar throughout the same family. [c] This value is consistent with the one previously described for the tri(ethylene)glycol congener.[21]

The SPR experiments clearly demonstrated that glycodendrimers **8**, **23**, and **25** exhibited much higher binding affinity compared to their corresponding monovalent derivatives **18**, **19**, and **20** due to "multivalent or glycoside cluster effect".[22] As expected, monomeric lactoside **20** represented a weaker ligand for PA-IL[18] while the addition of a TEG linker to the galactoside moiety (**19** *vs* **18**) allowed a 2-fold enhancement of the affinity for the lectin. Thus, the additional glucoside residue in lactosides is playing a detrimental effect which therefore cannot just be simply accounted for a longer linker. Interestingly, galactosylated dendrimer **8** exhibited low micromolar $IC_{50}$ values (0.22 µM) while most notably galactodendrimer **23** afforded one of the best ligand known to date with an $IC_{50}$ value of 37 nM that compared well with results obtained with multivalent conjugates built around flexible or rigid scaffolds.[23] Most notably, the multivalent presentation of TEGylated galactodendrimer **23** afforded one of the best ligand known to date with an $IC_{50}$ value of 37 nM. This result unambiguously highlights the key-role of linkers in the interactions with lectin, with a counter-balanced entropic cost due to their flexibility. Additionally, tri-dimensional distribution of terminal and optimized galactosides crucially contributed to high potencies since a substantial improvement (32-fold) was observed for each ligand in **23**, when compared to monomeric reference **19**, while weaker individual enhancements were obtained with congested (**8** *vs* **18**) or unoptimized (**20** *vs* **25**) conjugates (11-fold).

## Conclusions

In summary, we demonstrated that the structural diversity in the construction of "onion peel" dendrimers, accessible *via* both convergent and divergent routes, represents an additional strategy for the build-up of dense surface groups within low dendrimer generation. It also represents clear advantages over existing approaches by providing versatile hypercore building blocks. Moreover, by not restricting layer by layer syntheses with identical subunits, one can programme the physical/biophysical properties of the dendrimers, as exemplified here with TEG residues. Of particular interest in this instance, is the use of underexploited dipentaerythritol as an $A_6$ core molecule. In fact, work is now in progress for further application on this useful building block as an $AB_5$ moiety. The work presented herein will undoubtedly be useful to generate efficient and programmable multivalent antiadhesive agents against bacterial infections.[7a,24] Rationalization of the preferential binding mode(s) together with determination of the precise role of each structural parameter leading to high avidity ligands such as in compound **23** are under investigation. Multivalent "onion peel" inhibitors harbouring optimized sugar epitopes, notably containing aromatic residue, are also presently under the scope. Further applications as antiadhesins towards galectins,[17] or as vectors for vaccines or drug targeting nanomaterials[25] are also under investigation.

## Acknowledgements

This work was supported by a discovery grant from the National Science and Engineering Research Council of Canada (NSERC) and by a Canadian Research Chair in Therapeutic Chemistry.

## Notes and references

[a] *Pharmaqam, Department of Chemistry, University of Quebec a Montreal, C.P. 8888, Succ. Centre-Ville, Montreal, Quebec, Canada H3C 3P8. E-mail: roy.rene@uqam.ca*

*†Electronic Supplementary Information (ESI) available: See DOI: 10.1039/b000000x/*

1. (a) E. Buhleier, W. Wehner and F. Vögtle, *Synthesis*, 1978, 155−158; (b) A.-M. Caminade, C.-O. Turrin and J.-P. Majoral, *New J. Chem.*, 2010, **34**, 1512−1524; (c) S. Svenson and D. A. Tomalia, *Adv. Drug Deliver. Rev.*, 2005, **57**, 2106−2129; (d) M. A. Mintzer and M. W. Grinstaff, *Chem. Soc. Rev.*, 2011, **40**, 173−190; (e) M. Sowinska and Z. Urbanczyk-Lipkowska, *New J. Chem*., 2014, **38**, 2168-2203.
2. (a) D. A. Tomalia, H. Baker, J. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J. Ryder and P. Smith, *Polym. J.*, 1985, **17**, 117−132; (b) N. Launay, A.-M. Caminade and J.-P. Majoral, *J. Am. Chem. Soc.*, 1995, **117**, 3282−3283.
3. C. J. Hawker and J. M. J. Fréchet, *J. Am. Chem. Soc.*, 1990, **112**, 7638−7647.
4. F. Zeng and S. C. Zimmerman, *J. Am. Chem. Soc.*, 1996, **118**, 5326−5327.
5. K. L. Killops, L. M. Campos and C. J. Hawker, *J. Am. Chem. Soc.*, 2008, **130**, 5062−5064.
6. (a) N. Kottari, Y. M. Chabre, T. C. Shiao, R. Rej and R. Roy, *Chem. Commun.*, 2014, **50**, 1983−1985; (b) S. Chatani, M. Podgórski, C. Wang and C. N. Bowman, *Macromolecules*, 2014, dx.doi.org/10.1021/ma501418r.
7. (a) Y. M. Chabre and R. Roy, *Adv. Carbohydr. Chem. Biochem.*, 2010, **63**, 165−393;(b) Y. M. Chabre and R. Roy, *Curr. Top. Med. Chem.,*2008, **8**, 1237−1285; (c) Y. M. Chabre and R. Roy, *Chem. Soc. Rev*., 2013, **42**, 4657−4708; (d) O. Renaudet and R. Roy, *Chem. Soc. Rev.*, 2013, **42**, 4515−4517; (e) M. Gingras, Y. M. Chabre, M. Roy and R. Roy, *Chem. Soc. Rev*., 2013, **42**, 4823−4841.
8. R. Sharma, K. Naresh, Y. M. Chabre, R. Rej, N. K. Saadeh and R. Roy, *Polym. Chem.*, 2014, **5**, 4321−4331.
9. A. Dondoni and A. Marra, *Chem. Soc. Rev.*, 2012, **41**, 573−586; J. W. Chan, B. Yu, C. E. Hoyle and A. B. Lowe, *Chem. Commun.*, 2008, 4959−4961.
10. B. Neises and W. Steglich, *Angew. Chem. Int. Ed.*, 1978, **17**, 522−524.
11. H. C. Kolb, M. G. Finn and K. B. Sharpless, *Angew. Chem. Int. Ed.*, 2001, **40**, 2004−2021; P. Wu, A. K. Feldman, A. K. Nugent, C. J. Hawker, A. Scheel, B. Voit, J. Pyun, J. M. J. Fréchet, K. B. Sharpless and V. V. Fokin, *Angew. Chem. Int. Ed.*, 2004, **43**, 3928−3932.
12. S. Zhang and Y. Zhao, *Bioconjugate Chem.*, 2011, **22**, 523−528.
13. F. Li, S. Yamada, Basappa, A. Shetty, M. Sugiura and K. Sugahara, *Glycoconjugate J.*, 2008, **25**, 603−610.
14. K. M. Halkes, A. Carvalho de Souza, C. E. P. Maljaars, G. J. Gerwig and J. P. Kamerling, *Eur. J. Org. Chem.*, 2005, **2005**, 3650−3659.
15. Y. M.Chabre, A. Papadopoulos, A. Arnold and R. Roy, *Beilstein J. Org. Chem*., 2014, **10**, 1524−1535.
16. M. L. Talaga, N. Fan, A.L. Fueri, R. K. Brown, Y. M. Chabre, P. Bandyopadhyay, R. Roy and T. K. Dam, *Biochemistry,* 2014, **53**, 4445−4454.
17. (a) V. Percec, P. Leowanawat, H.-J. Sun, O. Kulikov, C. D. Nusbaum, T. M. Tran, A. Bertin, D. A. Wilson, M. Peterca, S. Zhang, N. P. Kamat, K. Vargo, D. Moock, E. D. Johnston, D. A. Hammer, D. J. Pochan, Y. Chen, Y. M. Chabre, T. C. Shiao, M. Bergeron-Brlek, S. André, R. Roy, H.-J. Gabius and P. A. Heiney, *J. Am. Chem. Soc.*, 2013, **135**, 9055−9077; (b) S. Zhang, R.-O. Moussodia, H.-J. Sun, P. Leowanawat, A. Muncan, C. D. Nusbaum, K. M. Chelling, P. A. Heiney, M. L. Klein, S. André, R. Roy, H.-J. Gabius and V. Percec, *Angew. Chem Int. Ed*., 2014, doi: 10.1002/anie.201403186.
18. (a) J. Rodrigue, G. Ganne, B. Blanchard, C. Saucier, D. Giguère, T. C. Shiao, A. Varrot, A. Imberty and R. Roy, *Org. Biomol. Chem.,* 2013, **11**, 6906–6918; (b) A. Imberty, Y. M. Chabre and R. Roy, *Chem-Eur. J.* 2008, **14**, 7490−7499; (c) J.-L. Reymond, M. Bergmann and T. Darbre, *Chem. Soc. Rev*., 2013, **42**, 4814-4822.
19. L. Harmand, S. Cadet, B. Kauffmann, L. Scarpantonio, P. Batat, G. Jonusauskas, N. D. McClenaghan, D. Lastécouères and J.-M. Vincent, *Angew. Chem. Int. Ed.*, 2012, **51**, 7137−7141.
20. H. Tamiaki, A. Shinkai and Y. Kataoka, J. *Photochem. Photobiol., A,* 2009, **207**, 115–125.
21. S. Cecioni, J.-P. Praly, S. E. Matthews, M. Wimmerová, A. Imberty and S. Vidal, *Chem. Eur. J.*, 2012, **18**, 6250−6263.
22. (a) Y. C. Lee and R. T. Lee, *Acc. Chem. Res.*, 1995, **28**, 321−327; (b) R. Roy, *Curr. Opin. Struct. Biol*. 1996, **6**, 692−702; (c) J. J. Lundquist and E. J. Toone, *Chem. Rev.*, 2002, **102**, 555−578.
23. (a) S. Cecioni, V. Oerthel, J. Iehl, M. Holler, D. Goyard, J.-P. Praly, A. Imberty, J.-F. Nierengarten and S. Vidal, *Chem. Eur. J.*, 2011, **17**, 3252−3261; (b) S. Cecioni, S. Faure, U. Darbost, I. Bonnamour, H. Parrot-Lopez, O. Roy, C. Taillefumier, M. Wimmerová, J.-P. Praly, A. Imberty and S. Vidal, *Chem. Eur. J.*, 2011, **17**, 2146−2159.
24. (a) A. Bernardi, J. Jimenez-Barbero, A. Casnati, C. De Castro, T. Darbre, F. Fieschi, J. Finne, H. Funken, K.-E. Jaeger, M. Lahmann, T. K. Lindhorst, M. Marradi, P. Messner, A. Molinaro, P. V. Murphy, C. Nativi, S. Oscarson, S. Penades, F. Peri, R. J. Pieters, O. Renaudet, J.-L. Reymond, B. Richichi, J. Rojo, F. Sansone, C. Schaffer, W. B. Turnbull, T. Velasco-Torrijos, S. Vidal, S. Vincent, T. Wennekes, H. Zuilhof and A. Imberty, *Chem. Soc. Rev.*, 2013, **42**, 4709−4727; (b) N. Berthet, B. Thomas, I. Bossu, E. Dufour, E. Gillon, J. Garcia, N. Spinelli, A. Imberty, P. Dumy and O. Renaudet, *Bioconjugate Chem.*, 2013, **24**, 1598−1611.
25. (a) S. André, P. J. C. Ortega, M. A. Perez, R. Roy and H.-J. Gabius, *Glycobiology* 1999, **9**, 1253−1261; (b) D. Giguère, S. André, M. A. Bonin, M. A. Bellefleur, A. Provencal, P. Cloutier, B. Pucci, R. Roy and H. J. Gabius, *Bioorg. Med. Chem*., 2011, **19**, 3280−3287; (c) S. André, B. Liu, H.-J. Gabius and R. Roy, *Org. Biomol. Chem*., 2003, **1**, 3909−3916; (d) N. Ahmad, H.-J. Gabius, S. André, H. Kaltner, S. Sabesan, R. Roy, B. Liu, F. Macaluso and C. F. J. Brewer, *Biol. Chem*., 2004, **279**, 10841−10847.